Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland

Figures & data

Figure 1 The RebiSmart™ device.

Image reproduced with permission from Merck Serono S.A. – Geneva, Switzerland, a branch of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.

Table 1 Rank and summary statistics of the recorded score for each of the ten device functions in the rank population

Rank	Function	Mean (standard deviation)	Median (range)
1 (most useful)	Hidden needle	3.3 (3.01)	2.0 (1–10)
2	Confirmation sound	3.9 (2.45)	3.0 (1–10)
3	Three doses in one cartridge	4.6 (2.32)	4.0 (1–10)
4	Injection button lights up	4.7 (2.16)	5.0 (1–9)
5	Stepwise injection guide on screen	5.6 (3.14)	6.0 (1–10)
6	Last injection indicator	5.6 (2.44)	6.0 (1–10)
7	Comfort settings	5.8 (2.56)	6.0 (1–10)
8	Dose indicator	6.1 (2.19)	6.0 (1–10)
9	Dose history calendar	7.5 (2.30)	8.0 (1–10)
10 (least useful)	Dose history list	8.0 (2.57)	9.0 (1–10)

Notes: n = 56. Secondary endpoint: top three device functions that patients found most useful.

Figure 2 Visual analog scale (VAS) scores representing patient opinion of the auto-injector in the population of patients who completed the trial at week 12.

Notes: n = 59. Primary endpoint: percentage of patients who liked using the device (VAS score of ≥6).

Figure 3 Number and percentage of responses to the “ease of use” question in the population of patients who completed the survey at week 12.

Notes: n = 59. Secondary endpoint: percentage of patients who found the device ‘easy’ or ‘very easy’ to use.